Matisse Capital’s Parabilis Medicines Inc PBLS Stock Holding History

Matisse Capital’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$559K	Buy	+17,300	New	+$604K	0.22%	100

Other funds holding PBLS

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Bell Investment Advisors Oakland, California $684M AUM 11.42% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Matisse Capital's PBLS Position: Q3 2026 in Review

Matisse Capital opened a new position in Parabilis Medicines Inc (PBLS) in Q3 2026: 17,300 shares worth $559K. The stake represents 0.22% of the portfolio and ranks #100 among its holdings.

17 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

Matisse Capital held 17,300 shares of Parabilis Medicines Inc worth $559K as of Q3 2026.
Parabilis Medicines Inc was a new Matisse Capital position in Q3 2026.
Parabilis Medicines Inc made up 0.22% of Matisse Capital's portfolio in Q3 2026, its #100 holding.
17 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q3 2026.

Based on Matisse Capital's 13F filing for Q3 2026, filed 29 Oct 2026.